The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes
暂无分享,去创建一个
[1] O. Cornely,et al. Tinea der freien Haut , 2010 .
[2] I. Rundshagen,et al. Leitlinien und Empfehlungen , 2008 .
[3] T. Young,et al. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. , 2010, The Cochrane database of systematic reviews.
[4] Melissa D Gover,et al. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.
[5] H. Korting,et al. Candidose der Haut , 2006 .
[6] A. Koç,et al. Terbinafine Versus Itraconazole and Fluconazole in the Treatment of Vulvovaginal Candidiasis , 2006, American journal of therapeutics.
[7] P. Nenoff,et al. Onychomykosen — eine retrospektive Untersuchung zum Erregerspektrum , 2006 .
[8] P. Nenoff,et al. Causative agents of onychomycosis — a retrospective study , 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[9] Wannasri Sindhupak,et al. A comparison of the efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis. , 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[10] E. Warshaw,et al. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis * , 2005, International journal of dermatology.
[11] M. Lecha,et al. Treatment options – development of consensus guidelines , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.
[12] S. Sengupta,et al. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. , 2005, Indian journal of dermatology, venereology and leprology.
[13] V. Buchta,et al. Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1‐day and a 3‐day regimen , 2005, Mycoses.
[14] A. Gupta,et al. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. , 2005, Medical mycology.
[15] H. Korting,et al. Influence of serum protein binding on theIn Vitro activity of anti-fungal agents , 1995, Infection.
[16] C. Evrüke,et al. Clinical and mycological efficacy of single‐day oral treatment with itraconazole (400 mg) in acute vulvovaginal candidosis , 2004, Mycoses.
[17] S. Chattopadhyay. Itraconazole: better choice to treat recurrent vulvovaginal candidoses. , 2004, Journal of the Indian Medical Association.
[18] J. Smolle,et al. Itraconazole in the Treatment of Tinea Capitis Caused by Microsporum canis: Experience in a Large Cohort , 2004, Pediatric dermatology.
[19] R. Sylvester,et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. , 2004, European journal of cancer.
[20] S. Kawana,et al. Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis , 2004, Mycoses.
[21] Andrew M. Johnson,et al. Cumulative meta‐analysis of systemic antifungal agents for the treatment of onychomycosis , 2004, The British journal of dermatology.
[22] A. Kawada,et al. Clinical and Pharmacokinetic Studies of Continuous Itraconazole for the Treatment of Onychomycosis , 2004, The Journal of dermatology.
[23] T. Nabeshima,et al. Intracutaneous Distributions of Fluconazole, Itraconazole, and Griseofulvin in Guinea Pigs and Binding to Human Stratum Corneum , 2004, Antimicrobial Agents and Chemotherapy.
[24] A. Biton,et al. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis , 2003, The Journal of dermatological treatment.
[25] S. Aman,et al. Itraconazole pulse therapy in the treatment of disto-lateral subungual onychomycosis. , 2003, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.
[26] C. Nappi,et al. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. , 2003, European journal of obstetrics, gynecology, and reproductive biology.
[27] S. Feldman,et al. Terbinafine Is More Effective Than Itraconazole In Treating Toenail Onychomycosis: Results from a Meta-analysis of Randomized Controlled Trials , 2003, Journal of cutaneous medicine and surgery.
[28] H. Korting,et al. Tinea capitis , 2002, Der Hautarzt.
[29] B. Sigurgeirsson,et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. , 2002, Archives of dermatology.
[30] Aditya K. Gupta,et al. Itraconazole is Effective in the Treatment of Tinea Capitis Caused by Microsporum Canis , 2001, Pediatric dermatology.
[31] R. Summerbell,et al. Therapeutic Options for the Treatment of Tinea Capitis Caused by Trichophyton Species: Griseofulvin Versus the New Oral Antifungal Agents, Terbinafine, Itraconazole, and Fluconazole , 2001, Pediatric dermatology.
[32] L. Patton,et al. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[33] Aditya K. Gupta,et al. Efficacy of Itraconazole, Terbinafine, Fluconazole, Griseofulvin and Ketoconazole in the Treatment of Scopulariopsis brevicaulis Causing Onychomycosis of the Toes , 2001, Dermatology.
[34] N. Shear,et al. A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis , 2000, Drug safety.
[35] B. Elewski. Onychomycosis. Treatment, quality of life, and economic issues. , 2000, American journal of clinical dermatology.
[36] A. Gupta,et al. Itraconazole and terbinafine in perspective. From petri dish to patient. , 1999, Postgraduate medicine.
[37] B. Sigurgeirsson,et al. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .
[38] W. Sterry,et al. Tinea capitis in Germany. A survey in 1998. , 1999, Mycoses.
[39] J. Remme,et al. Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea pedis und Tinea manuum: Vergleich zweier Behandlungsschemata , 1998, Mycoses.
[40] E. Epstein,et al. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. , 1998, Archives of dermatology.
[41] A. Gupta,et al. Itraconazole in the treatment of superficial cutaneous and mucosal Candida infections. , 1998, The Journal of the American Osteopathic Association.
[42] B. Piraccini,et al. Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.
[43] P. Stoffels,et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. , 1997, Journal of the American Academy of Dermatology.
[44] R. Schopf,et al. German randomized double–blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection , 1996, The British journal of dermatology.
[45] E. Lesaffre,et al. A 12–week treatment for dermatophyte toe onychomycosis terbinafine 250mg/day vs. itraconazole 200mg/day—a double‐blind comparative trial , 1996, The British journal of dermatology.
[46] K. Goa,et al. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. , 1996, Drugs.
[47] M. Ollert,et al. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group , 1995, Antimicrobial agents and chemotherapy.
[48] M. Cuétara,et al. ITRACONAZOLE VERSUS GRISEOFULVIN IN THE TREATMENT OF TINEA CAPITIS: A DOUBLE‐BLIND RANDOMIZED STUDY IN CHILDREN , 1994, International journal of dermatology.
[49] Y. Lau,et al. Chronic Mucocutaneous Candidiasis. , 2017, The journal of allergy and clinical immunology. In practice.
[50] D. Massart,et al. Two‐week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double‐blind, multicentre study , 1994, The British journal of dermatology.
[51] F. Barile,et al. [Comparative evaluation of fluconazole 50 mg and 100 mg versus itraconazole 100 mg in the treatment of dermatomycoses]. , 1994, La Clinica terapeutica.
[52] M. Heenen,et al. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. , 1994, Dermatology.
[53] M. Ollert,et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole , 1993, Antimicrobial Agents and Chemotherapy.
[54] J. V. van Cutsem,et al. Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. , 1992, Journal of the American Academy of Dermatology.
[55] H. Korting,et al. Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study , 1991, Antimicrobial Agents and Chemotherapy.
[56] H. Behrendt,et al. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. , 1990, Journal of the American Academy of Dermatology.
[57] R. Woestenborghs,et al. The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.
[58] H. Degreef,et al. Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.